Physician profile
Alexander S Foster
NPI 1033407275
$28,874.18
in general payments reported to CMS, 2019-2025
27 companies · $2,838 in 2025
The $2,838 reported for 2025 was more than what 88% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $832 · 2021: $808 · 2022: $16K · 2023: $6,697 · 2024: $846 · 2025: $2,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,135 · Food and Beverage: $2,163 · Entertainment: $57.29 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,135.00 |
| Food and Beverage | $2,163.03 |
| Entertainment | $57.29 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $17,724.01 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Johnson & Johnson Surgical Vision, INC. | $6,411.69 | 2019-2023 | Tecnis Simplicity, Tecnis Iol |
| Alcon Vision LLC | $1,834.63 | 2019-2024 | Clareon, Luxor, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $496.16 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $453.13 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Allergan, INC. | $258.33 | 2019-2022 | |
| Glaukos Corporation | $226.01 | 2020-2025 | Idosetr, Idose |
| Harrow Eye, LLC | $209.37 | 2024-2025 | Vevye |
| New World Medical,INC. | $165.79 | 2020 | |
| Novartis Pharmaceuticals Corporation | $165.38 | 2020-2023 | |
| Aerie Pharmaceuticals, INC. | $141.79 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $121.22 | 2019-2021 | |
| Oyster Point Pharma, INC. | $100.66 | 2022-2025 | Tyrvaya, Ryzumvi |
| Astellas Pharma US INC | $94.74 | 2024 | Izervay |
| Dompe US, INC. | $91.85 | 2019-2025 | Oxervate |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $75.60 | 2022-2024 | |
| Optos, INC. | $57.29 | 2023-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Thea Pharma INC. | $53.84 | 2022-2025 | Iyuzeh |
| Biotissue Holdings INC. | $45.00 | 2025 | |
| Sun Pharmaceutical Industries INC. | $27.25 | 2023 | Cequa |
| Eyevance Pharmaceuticals LLC | $20.29 | 2022 | |
| Shire North American Group INC | $19.34 | 2019 | |
| Beaver-Visitec International, INC. | $19.06 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $17.65 | 2024 | |
| Ivantis, INC | $15.28 | 2020 | |
| Amgen INC. | $14.51 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $14.31 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.